Español
Nederlands
Italiano
Deutsch
Français
Português
Laboratorios Farmacéuticos Rovi is expected to pay 1,1037 euros per share in dividends to its shareholders on July 10, 2024.
Thinking about dividends from Laboratorios Farmacéuticos Rovi (ROVI)? Make sure to buy before the Ex-dividend Date, July 8, 2024, and stay until the Record Date, July 9, 2024, to guarantee your eligibility.
Laboratorios Farmacéuticos Rovi (ROVI) credited 1.2938 euros in dividends on July 5, 2023.
Laboratorios Rovi does not have a defined dividend policy, so it is difficult to predict the amount to be distributed by dividend. However, with the exception of the year affected by the covid 19 pandemic, it has always paid its shareholders the first week of July.
By 2023, they expect a decline in consolidated net income due to the uncertainty that pharma will face in the wake of the pandemic.
So, despite the stock market and profit increase in 2021, it is not easy to foresee what Rovi will do with its dividends in 2023, 2024 or 2025.
Join +33,000 investors who get notifications, analysis and news.
Payout Ratio Laboratorios Farmacéuticos Rovi Dividends
Dividend calendar of Laboratorios Farmacéuticos Rovi
These are the most important events of the Laboratorios Farmacéuticos Rovi calendar in 2025:
| Event | Day |
|---|---|
| Last trading date | July 5, 2024 |
| Ex-Dividend (Ex-Date) | July 8, 2024 |
| Record date | July 9, 2024 |
| Date of payment | July 10, 2024 |
Dividend history of Laboratorios Farmacéuticos Rovi
In this table you can see the complete history:
| Year | Ex-Dividend | Amount | Total |
|---|---|---|---|
| 2023 | 07/03/2023 | 1.2938 € | 1.2938 € |
| 2022 | 07/05/2022 | 0.9556 € | 0.9556 € |
| 2021 | 07/05/2021 | 0.3812 € | 0.3812 € |
| 2020 | 11/17/2020 | 0.1751 € | 0.1751 € |
| 2019 | 07/02/2019 | 0.0798 € | 0.0798 € |
| 2018 | 07/03/2018 | 0.1207 € | 0.1207 € |
| 2017 | 07/03/2017 | 0.183 € | 0.183 € |
| 2016 | 06/30/2016 | 0.139 € | 0.139 € |
| 2015 | 07/02/2015 | 0.169 € | 0.169 € |
| 2014 | 07/03/2014 | 0.1612 € | 0.1612 € |
| 2013 | 07/03/2013 | 0.1366 € | 0.1366 € |
| 2012 | 07/04/2012 | 0.1269 € | 0.1269 € |
| 2011 | 07/06/2011 | 0.17208 € | 0.17208 € |
| 2010 | 07/06/2010 | 0.141 € | 0.141 € |
| 2009 | 07/08/2009 | 0.0865 € | 0.0865 € |
| 2008 | 09/17/2008 | 0.0783 € | 0.0783 € |
Information about Laboratorios Farmacéuticos Rovi
Laboratorios Farmacéuticos Rovi is a Spanish pharmaceutical company based in Madrid specialized in the research, development, manufacture and commercialization of generic drugs and pharmaceutical specialties.
Rovi focuses a large part of its efforts on the research and development of new drugs, having one of the largest R&D laboratories in Europe.
Rovi has achieved great milestones throughout its history, such as the patent of heparin or the agreement with the American pharmaceutical giant Pzifer to bring terramycin (an antibiotic with countless uses) to Spain in 1952. In recent years, specifically in July 2020, it was chosen by Moderna to manufacture the COVID-19 vaccine in Madrid as soon as it became available.
Frequently asked questions about Laboratorios Farmacéuticos Rovi dividends
Laboratorios Farmacéuticos Rovi pays dividends on a Anual basis.
Laboratorios Farmacéuticos Rovi is listed on the Madrid Stock Exchange and is part of the Ibex35.
Laboratorios Farmacéuticos Rovi has the Ticker or stock code ROVI.
The CEO of Laboratorios Farmacéuticos Rovi in 2025 is Mr. Juan Lopez-Belmonte Encina.
Laboratorios Farmacéuticos Rovi has a growing dividend program. In the last 5 years, dividends have been at least equal to or higher than the previous year.